{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:08:57Z","timestamp":1787166537951,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"am","delay-in-days":332,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017050","name":"Cycle for Survival","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ygyno.2025.09.007","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:04:16Z","timestamp":1759205056000},"page":"77-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Uterine leiomyosarcoma progression: A study of serial recurrences"],"prefix":"10.1016","volume":"202","author":[{"given":"Tiffany Y.","family":"Sia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Curtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier","family":"Selenica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Da Cruz Paula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Moufarrij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem R.","family":"Abu-Rustum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Mario M.","family":"Leitao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Weigelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martee L.","family":"Hensley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ygyno.2025.09.007_bb0005","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/ijc.22239","article-title":"Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26,758 cases","volume":"119","author":"Toro","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2025.09.007_bb0010","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ygyno.2017.02.019","article-title":"Uterine leiomyosarcoma: epidemiology, contemporary treatment strategies and the impact of uterine morcellation","volume":"145","author":"Ricci","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.09.007_bb0015","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/cncr.26333","article-title":"A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma","volume":"118","author":"Zivanovic","year":"2012","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2025.09.007_bb0020","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s41379-022-01011-z","article-title":"A novel morphology-based risk stratification model for stage I uterine leiomyosarcoma: an analysis of 203 cases","volume":"35","author":"Chapel","year":"2022","journal-title":"Mod. Pathol."},{"issue":"4","key":"10.1016\/j.ygyno.2025.09.007_bb0025","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/cncr.23245","article-title":"Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy","volume":"112","author":"Kapp","year":"2008","journal-title":"Cancer"},{"issue":"33","key":"10.1016\/j.ygyno.2025.09.007_bb0030","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.00454","article-title":"Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for high-grade uterine Leiomyosarcoma: a phase III NRG oncology\/gynecologic oncology group study","volume":"36","author":"Hensley","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"9 Suppl 3","key":"10.1016\/j.ygyno.2025.09.007_bb0035","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1097\/IGC.0000000000000261","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas","volume":"24","author":"Hensley","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2025.09.007_bb0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ygyno.2017.07.122","article-title":"Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: trends and survival outcomes","volume":"147","author":"Littell","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"14","key":"10.1016\/j.ygyno.2025.09.007_bb0045","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-19-3959","article-title":"Genomic landscape of uterine sarcomas defined through prospective clinical sequencing","volume":"26","author":"Hensley","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.ygyno.2025.09.007_bb0050","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1158\/1078-0432.CCR-17-3704","article-title":"Combination approach for detecting different types of alterations in circulating tumor DNA in Leiomyosarcoma","volume":"24","author":"Przybyl","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.ygyno.2025.09.007_bb0055","first-page":"2072","article-title":"Targeted next-generation sequencing of cancer genes identified frequent TP53 and ATRX mutations in leiomyosarcoma","volume":"7","author":"Yang","year":"2015","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.ygyno.2025.09.007_bb0060","series-title":"NCI Protocol 10250: A Phase II Study of Temozolomide and Olaparib for the Treatment of Advanced Uterine Leiomyosarcoma","author":"Ingham","year":"2020"},{"key":"10.1016\/j.ygyno.2025.09.007_bb0065","article-title":"Next-generation sequencing\u2013guided treatment of BRCA2-Mutant metastatic uterine leiomyosarcoma with poly(ADP-ribose) polymerase inhibitor therapy","volume":"8","author":"Kirkendoll","year":"2024","journal-title":"JCO Precis. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2025.09.007_bb0070","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1634\/theoncologist.2018-0448","article-title":"BRCA1\/2 functional loss defines a targetable subset in Leiomyosarcoma","volume":"24","author":"Seligson","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2025.09.007_bb0075","article-title":"Retrospective analysis of BRCA-altered uterine sarcoma treated with poly(ADP-ribose) polymerase inhibitors","volume":"9","author":"Rao","year":"2025","journal-title":"JCO Precis. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2025.09.007_bb0080","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann. Oncol."},{"issue":"7447","key":"10.1016\/j.ygyno.2025.09.007_bb0085","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2025.09.007_bb0090","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1200\/EDBK_350541","article-title":"Novel therapeutics in the treatment of uterine sarcoma","volume":"42","author":"Bose","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"4","key":"10.1016\/j.ygyno.2025.09.007_bb0095","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/CCO.0000000000000741","article-title":"Next-generation sequencing for the management of sarcomas with no known driver mutations","volume":"33","author":"Vyse","year":"2021","journal-title":"Curr. Opin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2025.09.007_bb0100","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41379-020-00705-6","article-title":"Targeted RNA expression profiling identifies high-grade endometrial stromal sarcoma as a clinically relevant molecular subtype of uterine sarcoma","volume":"34","author":"Momeni-Boroujeni","year":"2021","journal-title":"Mod. Pathol."},{"issue":"8","key":"10.1016\/j.ygyno.2025.09.007_bb0105","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/s41379-020-0514-3","article-title":"Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary","volume":"33","author":"Da Cruz","year":"2020","journal-title":"Mod. Pathol."},{"issue":"8","key":"10.1016\/j.ygyno.2025.09.007_bb0110","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/s41379-021-00799-6","article-title":"Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases","volume":"34","author":"da Silva","year":"2021","journal-title":"Mod. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.09.007_bb0115","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-integrated mutation profiling of actionable Cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J. Mol. Diagn."},{"issue":"10","key":"10.1016\/j.ygyno.2025.09.007_bb0120","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/nmeth.3069","article-title":"Accurate de novo and transmitted indel detection in exome-capture data using microassembly","volume":"11","author":"Narzisi","year":"2014","journal-title":"Nat. Methods"},{"issue":"16","key":"10.1016\/j.ygyno.2025.09.007_bb0125","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkw520","article-title":"FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing","volume":"44","author":"Shen","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.ygyno.2025.09.007_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.01.003","article-title":"Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients","volume":"185","author":"Nguyen","year":"2022","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ygyno.2025.09.007_bb0135","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nbt.2203","article-title":"Absolute quantification of somatic DNA alterations in human cancer","volume":"30","author":"Carter","year":"2012","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.09.007_bb0140","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/2159-8290.CD-17-0321","article-title":"Accelerating discovery of functional mutant alleles in Cancer","volume":"8","author":"Chang","year":"2018","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.ygyno.2025.09.007_bb0145","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13059-022-02794-9","article-title":"MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution","volume":"23","author":"Kaufmann","year":"2022","journal-title":"Genome Biol."},{"key":"10.1016\/j.ygyno.2025.09.007_bb0150","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/S0090-8258(21)00734-4","article-title":"CDKN2A loss-of-function genetic alterations in uterine sarcoma: prognostic implications and potential therapeutic target","volume":"162","author":"Miller","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.09.007_bb0155","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41467-017-02602-0","article-title":"Integrative genomic and transcriptomic analysis of leiomyosarcoma","volume":"9","author":"Chudasama","year":"2018","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.ygyno.2025.09.007_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082126","article-title":"Genomic database analysis of uterine Leiomyosarcoma mutational profile","volume":"12","author":"Astolfi","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.ygyno.2025.09.007_bb0165","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1158\/1078-0432.CCR-24-0148","article-title":"Developing novel genomic risk stratification models in soft tissue and uterine Leiomyosarcoma","volume":"30","author":"Dermawan","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.ygyno.2025.09.007_bb0170","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41379-021-01003-5","article-title":"ESR1 hotspot mutations in endometrial stromal sarcoma with high-grade transformation and endocrine treatment","volume":"35","author":"Dessources","year":"2022","journal-title":"Mod. Pathol."},{"issue":"12","key":"10.1016\/j.ygyno.2025.09.007_bb0175","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.ygyno.2025.09.007_bb0180","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","article-title":"ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.ygyno.2025.09.007_bb0185","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1158\/1078-0432.CCR-19-0271","article-title":"Genomic evolutionary patterns of Leiomyosarcoma and Liposarcoma","volume":"25","author":"Amin-Mansour","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.ygyno.2025.09.007_bb0190","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2022.33.e55","article-title":"Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052)","volume":"33","author":"Asano","year":"2022","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.09.007_bb0195","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/PO.20.00122","article-title":"Clinical outcome of Leiomyosarcomas with somatic alteration in homologous recombination pathway genes","volume":"4","author":"Rosenbaum","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.ygyno.2025.09.007_bb0200","article-title":"Retrospective analysis of BRCA-altered uterine sarcoma treated with poly (ADP-ribose) polymerase inhibitors","volume":"9","author":"Rao","year":"2025","journal-title":"JCO Precis. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.ygyno.2025.09.007_bb0205","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS11584","article-title":"Alliance A092104: a randomized phase 2\/3 study of olaparib plus temozolomide versus investigator\u2019s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy","volume":"41","author":"Lacuna","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2025.09.007_bb0210","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012020","article-title":"Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma","volume":"13","author":"Movva","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2025.09.007_bb0215","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1634\/theoncologist.2016-0310","article-title":"Clinical benefit in response to Palbociclib treatment in refractory uterine Leiomyosarcomas with a common CDKN2A alteration","volume":"22","author":"Elvin","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2025.09.007_bb0220","doi-asserted-by":"crossref","first-page":"3914232","DOI":"10.1155\/2019\/3914232","article-title":"Analysis of the CDK4\/6 cell cycle pathway in Leiomyosarcomas as a potential target for inhibition by Palbociclib","volume":"2019","author":"B\u00f6hm","year":"2019","journal-title":"Sarcoma"},{"key":"10.1016\/j.ygyno.2025.09.007_bb0225","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ygyno.2015.01.514","article-title":"PD-1, PD-L1 expression in 1599 gynecological cancers: implications for immunotherapy","volume":"137","author":"Herzog","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"17","key":"10.1016\/j.ygyno.2025.09.007_bb0230","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1002\/cncr.30738","article-title":"Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study","volume":"123","author":"Ben-Ami","year":"2017","journal-title":"Cancer"},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2025.09.007_bb0235","doi-asserted-by":"crossref","first-page":"11506","DOI":"10.1200\/JCO.2021.39.15_suppl.11506","article-title":"NCI protocol 10250: a phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma","volume":"39","author":"Ingham","year":"2021","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825010042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825010042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:38:08Z","timestamp":1780407488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825010042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":47,"alternative-id":["S0090825825010042"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.09.007","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uterine leiomyosarcoma progression: A study of serial recurrences","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}